comprehensive -WSS

comprehensive

author：focus 2025-09-28 02:26:51 - browse：879

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Flint parents haunted by uncertainty, fears of lead poisoning

entertainment

WSS

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

'Null' research findings aren't empty of meaning. Let's publish them

Burning questions for the 2024 JPM Healthcare Conference

How I helped Pfizer think through the ethics of Viagra

Alnylam reports growth in sales of rare disease treatments

When waiting feels immoral: Empathy in the emergency department

Wikipedia

comprehensive

knowledge

How to save PrEP access — and even expand it

U.K. sequencing study surfaces new findings about tumor DNA

How one medical school became remarkably diverse

Goldman Sachs launches $650M fund for life science investments

Activists slam private health insurers over coverage restrictions

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

U.K. sequencing study surfaces new findings about tumor DNA

Bright Health sells Medicare Advantage business to Molina

Ahead of JPM, here's who's profiting most in health care

knowledge

New weight loss drugs work. But how can they best be used?

How a scoliosis diagnosis changed the life of one young dancer

Physicians aren't 'burning out.' They're suffering from moral injury

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

UCB departs biotech trade group BIO

Feng Zhang CRISPR delivery startup lays off quarter of staff

knowledge

entertainment

focus

knowledge